Wharton S, Raiber L, Serodio K, Lee J, Christensen R
Diabetes Metab Syndr Obes. 2018; 11:427-438.
PMID: 30174450
PMC: 6109660.
DOI: 10.2147/DMSO.S171365.
Wong G, Wright J
Cochrane Database Syst Rev. 2014; (2):CD007452.
PMID: 24585007
PMC: 10603273.
DOI: 10.1002/14651858.CD007452.pub2.
Bowyer A
Calif Med. 1970; 112(2):58.
PMID: 18730252
PMC: 1501694.
Prichard B
Br J Clin Pharmacol. 1982; 13(1):51-60.
PMID: 6121573
PMC: 1401763.
DOI: 10.1111/j.1365-2125.1982.tb01336.x.
Prichard B, GILLAM P
Br Med J. 1969; 1(5635):7-16.
PMID: 5761914
PMC: 1981816.
DOI: 10.1136/bmj.1.5635.7.
Serum enzymes and propranolol.
Wilkinson R, Luetscher J, Goldman R
Br Med J. 1971; 2(5756):276-7.
PMID: 5572397
PMC: 1796413.
DOI: 10.1136/bmj.2.5756.276-c.
Propranolol and polythiazide in treatment of hypertension.
OBrien E, Mackinnon J
Br Heart J. 1972; 34(10):1042-4.
PMID: 5086971
PMC: 458544.
DOI: 10.1136/hrt.34.10.1042.
Controlled trial of propranolol in hypertension.
ZACHARIAS F, Cowen K
Br Med J. 1970; 1(5694):471-4.
PMID: 4907811
PMC: 1699423.
DOI: 10.1136/bmj.1.5694.471.
Treatment of hypertension with a new beta-blocking agent, pindolol (Visken).
Persson I, Ulrich J
Eur J Clin Pharmacol. 1973; 6(4):217-9.
PMID: 4591149
DOI: 10.1007/BF00644734.
Propranolol in hypertension. Report on 158 patients treated up to one year.
Hansson L, MALMCRONA R, Olander R, Rosenhall L, Westerlund A, Aberg H
Klin Wochenschr. 1972; 50(7):364-9.
PMID: 4554594
DOI: 10.1007/BF01486832.
Controlled trial of oxprenolol and practolol in hypertension.
LEISHMAN A, THIRKETTLE J, Allen B, Dixon R
Br Med J. 1970; 4(5731):342-4.
PMID: 4394369
PMC: 1819715.
DOI: 10.1136/bmj.4.5731.342.
Beta-adrenergic receptor blocking drugs in hypertension.
Simpson F
Drugs. 1974; 7(1):85-105.
PMID: 4152167
DOI: 10.2165/00003495-197407010-00006.
Tailoring antihypertensive drug therapy for the black patient.
ARRADONDO J
J Natl Med Assoc. 1987; 79(2):149-54.
PMID: 3560241
PMC: 2571459.
Racial differences in antihypertensive therapy: evidence and implications.
Weinberger M
Cardiovasc Drugs Ther. 1990; 4 Suppl 2:379-82.
PMID: 2271400
DOI: 10.1007/BF02603180.
The efficacy of beta-adrenoceptor and calcium-entry blockers in hypertensive blacks.
MBuyamba-Kabangu J, Tambwe M
Cardiovasc Drugs Ther. 1990; 4 Suppl 2:389-94.
PMID: 1980202
DOI: 10.1007/BF02603182.
Hypotensive effect of oxprenolol in mild to moderate hypertension: a multicentre controlled study.
Motolese M, MUIESAN G, Colombi A
Eur J Clin Pharmacol. 1975; 8(1):21-31.
PMID: 786673
DOI: 10.1007/BF00616411.
beta-Adrenoceptor blocking effects and pharmacokinetics of pindolol. A study in hypertensive Africans.
Salako L, Falase A, Ragon A, Adio R
Eur J Clin Pharmacol. 1979; 15(5):299-304.
PMID: 37094
DOI: 10.1007/BF00558431.
The second Lilly Prize Lecture, University of Newcastle, July 1977. beta-Adrenergic receptor blockade in hypertension, past, present and future.
Prichard B
Br J Clin Pharmacol. 1978; 5(5):379-99.
PMID: 26370
PMC: 1429347.
DOI: 10.1111/j.1365-2125.1978.tb01644.x.
Uses of beta-adrenoceptor blocking drugs.
Prichard B, McDevitt D, Shanks R
J R Coll Physicians Lond. 1976; 11(1):35-57.
PMID: 10438
PMC: 5368760.
Haemodynamic effects of beta-adrenorecptor blockers in hypertension.
Ablad B, LJUNG B, SANNERSTEDT R
Drugs. 1976; 11 SUPPL 1:127-34.
PMID: 6245
DOI: 10.2165/00003495-197600111-00028.
